Clinical trials: Chronic Hepatitis B Patients With HBeAg-positive
Hepatitis B, Chronic
Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB
Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that has been widely used in mainland China for the treatment of chronic hepatitis B (CHB).
- Trial name
- NCT06743438
- Testing
- Tenofovir Amibufenamide（TMF）
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Hepatitis B
HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance
This study proposes to compare the effect of 48 weeks exposure to pegylated interferon alpha vs. nucleoside analogue (NA) on hepatitis B e antigen (HBeAg) seroconversion and HBsAg levels in nucleoside analogue controlled…
- Trial name
- NCT01769833
- Testing
- PEG-interferon-Alfa-2A, Nucleosides
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Pusan National University Hospital
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01519921
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 7 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam
This prospective, multicenter, observational study will evaluate the sustained response in patients with HBeAg positive chronic hepatitis B who are treated with Pegasys according to standard of care and in line with the current…
- Trial name
- NCT01886300
- Where
- 3 sites in Vietnam
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
- Trial name
- NCT02452528
- Testing
- ARC-520, Entecavir, Tenofovir
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis B
Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
This is a prospective, randomized, multicenter, open-label study. After more than 24 weeks NA treatment, HBeAg positive CHB patients who achieved HBV DNA<1000copies/ml but HBeAb negative, will be randomized (1:1) into 2 study…
- Trial name
- NCT02474316
- Testing
- Peginterferon alfa-2a, nucleos(t)ide analgoue
- Where
- 3 sites in China
- Volunteers
- 366 people
- Sponsor
- Ruijin Hospital
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV).
- Trial name
- NCT00436163
- Testing
- Peginterferon alfa-2a
- Where
- 9 sites in Estonia, Latvia and 1 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B
Currently, seven medications are approved for the treatment of hepatitis B: two formulations of interferon and five nucleons(t)ide analogues.
- Trial name
- NCT01906580
- Testing
- Peg-IFNα-2a, Entecavir
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Beijing 302 Hospital
Hepatitis B Virus
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary purpose of this amendment is…
- Trial name
- LIRA-B (NCT01204762)
- Testing
- pegIFN, pegIFNα-2a, PegIFN lambda
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment
The aim of interferon therapy in HBeAg positive chronic hepatitis B was to make patients obtain immune control to hepatitis B virus defined as occurred HBeAg seroconversion and HBsAg loss with sustained viral response after…
- Trial name
- NCT02368288
- Testing
- entecavir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis, Hepatitis B
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.
- Trial name
- QUASH 1 (NCT00496002)
- Testing
- Clevudine, Adefovir
- Where
- 134 sites in United States, Argentina and 10 more
- Sponsor
- Pharmasset
Hepatitis B, Chronic
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).
- Trial name
- NCT04439539
- Testing
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV…
- Trial name
- NCT02791269
- Testing
- Peginterferon alfa-2a
- Where
- 6 sites in New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
HBsAg Related Response Guided Therapy
Primary objective: Compare Pegasys RGT overall response rate (i.e., HBeAg seroconversion rate) with Pegasys mono historical response rate at week 72 (48 week treatment with 24 week follow up) Secondary objective : The changes of…
- Trial name
- S-RGT (NCT01456312)
- Testing
- Peginterferon alfa-2a, Entecavir
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Gangnam Severance Hospital
Chronic Hepatitis b
HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients
This is a open-label study to evaluate the safety and efficacy of autologous T-cells transfected with messenger ribonucleic acid (mRNA) encoding Hepatitis-B virus (HBV) antigen specific T cell receptor (TCR) in combination with…
- Trial name
- NCT06885710
- Testing
- LioCyx-M
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Changhai Hospital
Chronic Hepatitis B Virus, Pediatric
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection
- Trial name
- NCT01079806
- Testing
- Entecavir
- Where
- 44 sites in United States, Argentina and 12 more
- Volunteers
- 180 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
This open-label, multi-center study will evaluate the effect on the quantitative HBsAg reduction of peginterferon alfa-2a [PEGASYS] in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01086085
- Testing
- Adefovir, peginterferon alfa-2a [PEGASYS]
- Where
- 11 sites in China
- Volunteers
- 265 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated.
- Trial name
- NCT01011738
- Where
- 249 sites in Austria, Bahrain and 25 more
- Volunteers
- 1,842 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604212
- Testing
- ARC-520, entecavir, antihistamine
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis B
Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir
Oral antiviral drugs which can be given to patients with HBeAg-positive chronic hepatitis B include Lamivudine, Clevudine, Adefovir, Telbivudine, Entecavir and Tenofovir.
- Trial name
- TETRA (NCT01588912)
- Testing
- Telbivudine, Tenofovir, Entecavir
- Where
- 10 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Pusan National University Yangsan Hospital